Tuvirumab

Names

[ Name ]:
Tuvirumab

Biological Activity

[Description]:

Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research[1][2].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> HBV

[In Vivo]

Tuvirumab (OST 577; SDZ-OST 577; 5 mg/kg; iv; single dose) followed by intravenous wild-type HBV, the MS-2 strain, directs against the a determinant of HBV surface antigen delayed but does not prevent experimental infection of HBV and hepatitis in the chimpanzee[1]. Tuvirumab (5 mg/kg; iv) has a half-life of 16.7 days in the chimpanzee[1].

[References]

[1]. N Ogata, et al. Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3014-8.

[2]. R A Heijtink, et al. Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes. J Med Virol. 2001 Aug;64(4):427-34.

Chemical & Physical Properties

No Any Chemical & Physical Properties